Dalfampridine: Review Analysis on Multiple Sclerosis and Parkinson?s disease related to Waking Disability
Received Date: Nov 29, 2022 / Accepted Date: Dec 26, 2022 / Published Date: Dec 27, 2022
Abstract
The Multiple sclerosis and Parkinson’s disease are neurodegenerative disease which effect on the central nervous system. Which loss the coordination between brain and body multiple sclerosis is the progressive, autoimmune disease. It occurs when your immune system attack myelin cell in your brain and spinal cord. Parkinson’s disease is caused by the loss of dopamine in a part of your brain called substantial nigra, which causes and cure are unknown. MS disease are commonly occurs in young adult i.e. 20to 40 years where as Parkinson’s disease commonly occurs in old persons i.e. 60 years. Both the disease do not occur in same person, both disease loss the coordination of brain and body related to gait dysfunction. Dalfampridine is one of the available treatments for to improve the walking in MS and Parkinson’s disease related to gait dysfunction. Dalfampridine is the oral potassium channel blocker which was recently approved by FDA for sympathomimetic treatment in MS. Dalfampridine which acts on central and peripheral nervous system enhances conduction in demyelinated axon and improves waking ability of MS patient.
Citation: Shaikh T (2022) Dalfampridine: Review Analysis on Multiple Sclerosisand Parkinson’s disease related to Waking Disability. J Pharmacokinet Exp Ther6: 156. Doi: 10.4172/jpet.1000156
Copyright: © 2022 Shaikh T. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
ºÚÁÏÍø Journals
Article Tools
Article Usage
- Total views: 1142
- [From(publication date): 0-2022 - Nov 23, 2024]
- Breakdown by view type
- HTML page views: 926
- PDF downloads: 216